Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis (Q40154356)

18 September 2017

Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis (English)

1 reference

18 September 2017

0 references

Yohei Ichimura

1

1 reference

18 September 2017

Yoshihide Asano

2

1 reference

18 September 2017

Kaname Akamata

3

1 reference

18 September 2017

Takehiro Takahashi

4

1 reference

18 September 2017

Shinji Noda

5

1 reference

18 September 2017

Takashi Taniguchi

6

1 reference

18 September 2017

Tetsuo Toyama

7

1 reference

18 September 2017

Naohiko Aozasa

8

1 reference

18 September 2017

Hayakazu Sumida

9

1 reference

18 September 2017

Yoshihiro Kuwano

10

1 reference

18 September 2017

Koichi Yanaba

11

1 reference

18 September 2017

Yayoi Tada

12

1 reference

18 September 2017

Makoto Sugaya

13

1 reference

18 September 2017

Shinichi Sato

14

1 reference

18 September 2017

Takafumi Kadono

15

1 reference

18 September 2017

29 November 2013

1 reference

Archives of Dermatological Research

18 September 2017

1 reference

18 September 2017

306

1 reference

18 September 2017

4

1 reference

18 September 2017

331-338

1 reference

https://scigraph.springernature.com/pub.10.1007/s00403-013-1431-9

18 September 2017

0 references

cites work

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Future treatments in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Release of CXC-chemokines by human lung microvascular endothelial cells (LMVEC) compared with macrovascular umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Chemokine-cytokine cross-talk. The ELR+ CXC chemokine LIX (CXCL5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase-NF-kappa B pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Elevated matrix metalloproteinase-9 in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Topical antisense oligonucleotide therapy against LIX, an enterocyte-expressed CXC chemokine, reduces murine colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by decreasing joint vascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Serum levels of ADAM12-S: possible association with the initiation and progression of dermal fibrosis and interstitial lung disease in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

10.1007/S00403-013-1431-9

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference